Selective estrogen receptor modulators (SERMs) and retinoids in breast cancer chemoprevention

Environmental and Molecular Mutagenesis

Volumn 39, Issue 2-3, 2002, Pages 264-270

  Zujewski, Joanne ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Chemoprevention; Fenretinide; Insulin like growth factor 1; Raloxifene; Selective estrogen receptor modulator; Tamoxifen

Indexed keywords

ARZOXIFENE; BENZOTHIOPHENE DERIVATIVE; DROLOXIFENE; FENRETINIDE; IDOXIFENE; RALOXIFENE; RETINOID DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE;

BREAST CANCER; CANCER INHIBITION; CANCER INVASION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONFERENCE PAPER; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIUM CANCER; HUMAN; PHARMACODYNAMICS;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; FENRETINIDE; HUMANS; INCIDENCE; INSULIN-LIKE GROWTH FACTOR I; MULTICENTER STUDIES; RALOXIFENE; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ESTROGEN; RISK ASSESSMENT; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

RODENTIA; TRIXIS;

EID: 0036211685     PISSN: 08936692     EISSN: None     Source Type: Journal    
DOI: 10.1002/em.10054     Document Type: Conference Paper

References (69)

1. Chemoprevention of mammary carcinogenesis in the rat: Combined use of raloxifene and 9-cis-retinoic acid
2. Interference of the IGF system as a strategy to inhibit breast cancer growth
3. Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice
4. Reproductive endocrine and endometrial effects of raloxifene hydrochloride, a selective estrogen receptor modulator, in women with regular menstrual cycles
5. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats
6. Mammographic densities and risk of breast cancer among subjects with a family history of this disease
7. Mammographic features and breast cancer risk: Effects with time, age, and menopause status
8. Effect of tamoxifen on mammographic density
9. Pilot trial of the safety, tolerability, and retinoid levels of N-(4-hydroxyphenyl) retinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer
10. Tolerability of the synthetic retinoid Fenretinide (HPR)
11. Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in post-menopausal women. Two-year findings from the multiple outcomes of raloxifene (MORE) trial
12. Drop-outs in tamoxifen prevention trials
13. Effect of the synthetic retinoid fenretinide on dark adaptation and the ocular surface
14. Chemoprevention of breast cancer: The Italian experience
15. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
16. Can fenretinide protect women against ovarian cancer?
17. Tamoxifen for early breast cancer: An overview of the randomised trials
18. 4-Hydroxyphenyl retinamide is a highly selective activator of retinoid receptors
19. Regulation of estrogen receptor alpha function in breast cancer
20. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
21. Interaction of retinoids and tamoxifen on the inhibition of human mammary carcinoma cell proliferation
22. Inhibition of human mammary carcinoma cell proliferation by retinoids and intracellular cAMP-elevating compounds
23. Synthetic retinoid fenretinide is effective against a human ovarian carcinoma xenograft and potentiates cisplatin activity
24. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually
25. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer
26. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): An RXR-selective ligand
27. Clinical potential of new antiestrogens
28. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer
29. Tamoxifen induces hepatocellular carcinoma in rat liver: A 1-year study with two antiestrogens
30. Comparison of N-(4-hydroxyphenyl)retinamide and all-trans-retinoic acid in the regulation of retinoid receptor-mediated gene expression in human breast cancer cell lines
31. Tamoxifen breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2
32. Clinical development of estrogen modulators for breast cancer chemoprevention in premenopausal vs. post menopausal women
33. Phase I clinical trial of alitretinoin and tamoxifen in breast cancer patients: Toxicity, pharmacokinetic, and biomarker evaluations
34. Retinoids as preventive and therapeutic anticancer agents (Part I)
35. Retinoids in cancer chemoprevention
36. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women
37. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer
38. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment
39. Basic guide to the mechanisms of antiestrogen action
40. Re: Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer
41. Chemoprevention of MNU-induced mammary tumors in the mature rat by 4-HPR and tamoxifen
42. The incidence of hepatocellular carcinoma in US white women with breast cancer after the introduction of tamoxifen in 1977
43. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study
44. Potential role of tamoxifen in prevention of breast cancer
45. Growth hormone treatment induces mammary gland hyperplasia in aging primates
46. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice
47. Regulation of breast cancer growth by insulin-like growth factors
48. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites
49. Role of retinoic acid receptor overexpression in sensitivity to fenretinide and tumorigenicity of human ovarian carcinoma cells
50. Antiestrogenic properties of keoxifene, trans-4-hydroxytamoxifen, and ICI 164384, a new steroidal antiestrogen, in ZR-75-1 human breast cancer cells
51. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial
52. The Royal Marsden Hospital pilot tamoxifen chemoprevention trial
53. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women
54. Is tamoxifen effective in prevention of breast cancer?
55. Retinoic acid receptor beta expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide
56. N-(4-Hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma
57. Retinoids in cancer therapy
58. Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk
59. Chemoprevention of cancer
60. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids)
61. Effect of fenretinide on plasma IGF-I and IGFBP-3 in early breast cancer patients
62. The effects of retinoids on proliferative capacities and macromolecular synthesis in human breast cancer MCF-7 cells
63. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention study
64. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer
65. Effect of N-(4-hydroxyphenyl)retinamide on apoptosis in human breast cancer cells
66. Prevention-therapy-basic science and the resolution of the cancer problem
67. Average annual rates of invasive and noninvasive breast cancer by history of LCIS and atypical hyperplasia for participants in BCPT
68. Tamoxifen and secondary tumours. An update
69. The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat